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S1
CCR9 does not affect the representation or development of thymic cDC subsets.
S2
Migration of endogenous pDCs to the thymus is
CCR9-dependent.
S3
Phenotype of CpGA-activated versus unactivated pDCs from peripheral lymphoid tissues.
S4
Thymic homing of pDCs is CCR9-dependent. 4 S5
OVA-loaded pDCs fail to efficiently delete OVAspecific double positive CD4+ CD8+ thymocytes.
Figure S1 (related to Figure 1 ). CCR9 does not affect the representation or development of thymic cDC subsets. A. Thymi from untreated C57BL/6 (WT) mice were digested with Collagenase IV/DNase I and cell suspensions were analyzed by flow cytometry. Gating strategy for thymic pDCs (Lin-CD11c int B220+ PDCA-1+) and cDCs (Lin-CD11c hi B220-PDCA-1-) is shown. Thymic cDCs were further gated on "migratory" SIRPα+ (CD11b+) and "resident" SIRPα-(CD11b-) cDCs. Representative FACS plot shown from 4-5 mice per cohort in each experiment with 2 experiments performed. B. Bone marrow chimeras (BMC) were generated as described in Figure 1 by co-injecting equal numbers of either "experimental" Ccr9 -/-(CD45.2+) bone marrow (BM) cells (white bars) or "control" WT (CD45.2+) BM cells (black bars) together with congenic WT CD45.1+ BM cells into lethally irradiated F1 (CD45.1+ CD45.2+) recipients. Tissues were harvested 8-12 weeks after BM transfer and analyzed for expression of allelic CD45.1 and CD45.2 markers by flow cytometry. Quadrant gates were set based on isotype controls.
To normalize for the engraftment efficiency of each donor type, the CD45.1/CD45.2 ratio for BM-derived splenic CD19+ B cells was determined. For each mouse thymus, the CD45.1/CD45.2 ratio among gated (Lin-CD11c int , B220+) pDCs, (SIRPα+ CD11b+ CD11c+, B220-, Lin-) "migratory" SIRPα+ and (SIRPα-CD11b-CD11c+, B220-, Lin-) "resident" SIRPα-cDCs was normalized for the engraftment efficiency to yield normalized localization ratios (R): R= (CD45.1/CD45. 2) . Migration of endogenous pDCs to the thymus is CCR9-dependent. Congenic WT C57BL/6 (CD45.1+) and Ccr9 -/-(CD45.2+) mice were surgically joined at the flanks to establish a shared circulation (parabiosis). Thymi and blood were harvested after 3 weeks and analyzed for expression of allelic CD45.1 and CD45.2 markers by flow cytometry among partnerderived, fully differentiated pDCs (Lin-CD11c int PDCA-1+). Representative FACS plots for pDC gating strategy and for the presence of allelic markers from one of 7 parabiotic pairs of mice. See -/-(CD45.2) donor mice, whose T cells express an OVA-specific T cell receptor. 14d after reconstitution, mice were either untreated or injected i.v.daily for 2 consecutive days with 2-5 X 10 6 unpulsed (pDC), OVA peptidepulsed pDCs (pDC/OVA) or with 50 nmol of soluble OVA peptide in PBS (OVAp) as a positive control for clonal deletion of OVA-specific thymocytes. CD4+ CD8+ double positive (DP) thymocytes were analyzed two days after final pDC or OVA treatment, by gating on lineage-DP thymocytes to assess the frequency of the CD45.2+ OVA-specific population. A. Representative FACS plots illustrating the contribution of OVA-specific (CD45.2+) thymocytes among total DP thymocytes in untreated mice or after treatment of recipient mice with soluble OVAp, unpulsed or OVA-pulsed pDCs. B. Mean percent of OVA-specific CD45.2+ cells among total DP thymocytes, with SEM (N=5). Representative of 3 experiments with similar results. See 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Reaggregated Thymic Organ Culture (RTOC).
Thymi of OVA-specific TCR transgenic OT-II Rag1 -/-mice were dissociated by Collagenase IV and DNase I digestion as described (Gray et al., 2006; Hamazaki et al., 2007; Jenkinson et al., 1992) in 0.125% trypsin for 30 mins at 37ºC. Endogenous DCs were removed by pan DC microbead (Miltenyi Biotec) staining followed by MACS depletion. 1-5 X 10 5 pDCs sorted from Flt3L-B16 injected WT or Ccr9 -/-mice that were either unpulsed or have been previously loaded with 50µM of OVA 323-339 peptide for 2hrs (37 0 C) and extensively washed, were pelleted together with 1-5 million DC-depleted thymocytes, including stromal cells. The pelleted cells were reaggregated onto 0.8µm polycarbonate membrane filters (Sterilitech, Kent, WA), which were floated on 3ml of complete RPMI-1640 media (containing 10% FBS and antibiotics) in 6-well plates for 72-96 hrs at 37 0 C. Control wells contained 1µM or no OVA peptide. Reaggregated cells were harvested by brief treatment with 0.125% trypsin for 5-10 mins (37 0 C) and stained for intracellular Foxp3 among CD3+ CD4+ CD8-transgenic T cells to determine Treg induction or Annexin V and PI staining, using standard protocols, to determine the degree of clonal deletion by apoptosis after exclusion of PI+ necrotic cells.
Endocytic FITC-Dextran Assay.
Cells were resuspended in complete RPMI 1640 with 10% FCS and incubated with 0.1mg/ml of FITCDextran (MW = 40,500; Sigma-Aldrich) for 30 mins at 37 0 C. Cells were washed three times with icecold PBS and 1% bovine serum albumin, and labeled on ice with fluorochrome-conjugated mAbs.
In vivo FITC-Dextran administration. 2mg of FITC-Dextran (MW = 40,500, Sigma-Aldrich) or control Dextran (Sigma-Aldrich) was administered s.c. into normal C57BL/6 WT or Ccr9 -/-mice at the base of the tail in 200µl saline. In separate cohorts of WT mice, 2mg of FITC-Dextran was co-injected s.c. with 50 nmols of CpGA (ODN 1585, Invivogen) in 200µl of saline or mice given FITC-Dextran s.c. once were also treated with either 250-500 µg of α 4 mAb i.v. or saline every 12 hrs for 48 hrs prior to harvesting the tissues. In separate experiments, we injected 50µl of FITC-dextran (10 mg/ml) and Alexa Fluor 647-dextran (10 mg/ml in saline; MW = 10,000, Invitrogen) into the left and right footpads respectively. Controls include 50µl injections of FITC-dextran into the left footpad only, or injection of Alexa Fluor 647-dextran into the right footpad only. Thymi were digested 48 hrs later in Liberase 2 (Roche, Basel, Switzerland) and 1U/ml of DNase I (Sigma-Aldrich) for 30 mins at 37 0 C and single-cell suspensions were prepared, incubated with fluorochrome-conjugated mAbs and analyzed by flow cytometry. The number of FITC+ Lin-CD11c int B220+ pDCs per million thymocytes was determined.
Immunoflurescence of Thymic DC suspensions.
For visualization of thymic DCs containing endocytosed dextran, thymic cell suspensions from normal C57BL/6 mice treated s.c. with 2mg FITC-Dextran were briefly digested with collagenase IV and DNaseI as previously described and single cell suspensions were enriched for DCs using the Pan DC isolation MACS beads (Miltenyi Biotec) according to the manufacturer's directions. DC-enriched cells were immobilized on Alcian Blue treated coverslips, fixed in 2% Paraformaldehyde, and stained with AF647-conjugated (blue) anti-CD11c mAb (clone N418, eBioscience) and biotinylated anti-PDCA-1 mAb (clone ebio927, eBioscience) followed by a secondary staining with Streptavidin-conjugated A546 (red) (Molecular Probes) to detect the presence of FITC-Dextran (green) in thymic DC populations.
